
Thomas E Stinchcombe MD
Hematologic Oncology, Thoracic Cancer
Professor of Medicine, Duke University
Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Phone+1 919-966-4996
Fax+1 919-843-5515
Dr. Stinchcombe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1998 - 2001
- University of MichiganResidency, Internal Medicine, 1995 - 1998
- University of Virginia School of MedicineClass of 1995
Certifications & Licensure
- NC State Medical License 1998 - 2025
- MI State Medical License 1995 - 1998
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2006 Jan 01
- Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Start of enrollment: 2005 May 01
- Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC Start of enrollment: 2006 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: pre-clinical and phase 2 clinical trial results.Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder, Gregory M Cote, Glenn J Hanna
Clinical Cancer Research. 2025-08-11 - Early-Phase Trials in.Thomas E Stinchcombe, Gini F Fleming, Charles Craddock, Andrew H Ko, Eileen M O'Reilly
Journal of Clinical Oncology. 2025-07-01 - The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503...Nasser Altorki, Bryce Damman, Xiaofei Wang, Moishe Liberman, Dennis Wigle
The Journal of Thoracic and Cardiovascular Surgery. 2025-06-16
Press Mentions
- Role of Neoadjuvant Targeted Therapies Remains Unclear in NSCLCAugust 1st, 2025
- Taletrectinib Approved for NSCLCJune 11th, 2025
- Pre-Op Osimertinib in Lung Cancer Leads to More Major Pathologic ResponsesJune 3rd, 2025
- Join now to see all
Grant Support
- Clinical Trial: Phase I Trial Of Abraxane In Combination With Gemcitabine In SolNational Center For Research Resources2008
- Clinical Trial: Cisplatin/Etoposide Or Carboplatin/Pemetrexed In Patients With SNational Center For Research Resources2008
- Phase I Trial Of Abraxane In Combination With Gemcitabine In Solid TumorsNational Center For Research Resources2007
- Lccc 0412: Phase I Carboplatin And Abraxane In Patients With Solid TumorsNational Center For Research Resources2006–2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: